Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Bria, Emilio, Pilotto, Sara, Amato, Eliana, Fassan, Matteo, Novello, Silvia, Peretti, Umberto, Vavalà, Tiziana, Kinspergher, Stefania, Righi, Luisella, Santo, Antonio, Brunelli, Matteo, Corbo, Vincenzo, Giglioli, Eliana, Sperduti, Isabella, Milella, Michele, Chilosi, Marco, Scarpa, Aldo, Tortora, Giampaolo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Clinical Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494974/
https://ncbi.nlm.nih.gov/pubmed/25904052
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia